Resveratrol improves lipid profile and recovers heart function in postoperative CABG patients

Cardiovascular diseases (CVD), especially coronary artery disease (CAD), are among the most important causes of mortality in the world. Coronary artery bypass grafting (CABG) is a standard treatment for this disease, but it may be associated with complications in the postoperative period. This study investigated the effect of resveratrol (RES), a potent antioxidant and anti-inflammatory molecule, on cardiovascular indices and oxidative stress in patients after CABG surgery. This randomized, double-blind, placebo-controlled trial was carried out at the Bushehr Heart Center in Bushehr, Iran. A total of 60 patients undergoing CABG were randomly assigned in equal numbers to either the intervention group or the control group. The intervention group received RES capsules for 60 days, and the control group received a placebo for the same duration. Cardiovascular function and biochemical parameters, including lipid profile, cardiac enzymes, and markers of oxidative stress and inflammation, were measured at the beginning and end of the intervention. Compared to the control group, RES intake significantly reduced systolic blood pressure (SBP), triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL), and improved ejection fraction (EF). Although decreases in cardiac enzymes, including creatine phosphokinase (CPK) and lactate dehydrogenase (LDH), were observed in the RES group, these changes were not statistically significant. Also, the two groups showed no significant differences in diastolic blood pressure (DBP), HDL, or oxidative stress markers. RES supplementation protects patients after CABG by improving cardiovascular function and lipid profiles.Trial registration: IRCT20111119008129N12, first trial registration date: 2022-06-18.